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Abstract
Background: Sarpogrelate is expected to reduce restenosis by protecting blood vessels from oxidative stress and
vascular endothelial dysfunction as well as by acting as an antiplatelet agent after endovascular treatment (EVT).
This trial was designed to compare aspirin plus sustained-release (SR) sarpogrelate with aspirin plus clopidogrel
for the prevention of restenosis in patients with femoro-popliteal (FP) peripheral artery disease (PAD) who
underwent EVT.
Methods/Design: This is an open label, multicenter, prospective randomized controlled clinical trial. Patients will
be eligible for inclusion in this study if they require EVT for stenosis or occlusion of a de novo FP lesion. Patients
in each group will receive aspirin 100 mg with clopidogrel 75 mg or aspirin 100 mg with SR sarpogrelate 300 mg
(Anplone®) orally once a day for six months. The primary outcome of the study is the restenosis rate, defined as
> 50% luminal reduction by computed tomography angiography or catheter angiography in the six-month follow-
up period. Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation,
all-cause mortality, and all adverse events that take place in those six months.
Discussion: This study is a multicenter randomized controlled trial designed to show non-inferiority in terms of
the re-stenosis rate of SR sarpogrelate compared to clopidogrel for EVT for PAD in FP lesion patients.
Trial registration: ClinicalTrials.gov, NCT02959606. Registered on 9 November 2016.
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Background
After endovascular treatment (EVT) for peripheral artery
disease (PAD), antiplatelet agents are used for three pur-
poses: to prevent early thrombosis; to maintain long-term
patency; and to reduce the incidence of cardiovascular
events. Aspirin-based monotherapy or dual antiplatelet
therapy (DAPT) are the most commonly used methods for
these purposes [1]. Even though the common guidelines for
PAD suggest mono-antiplatelet therapy, monotherapy alone
may not be enough [2–5]. Surprisingly, however, there is no
evidence-based recommendation for optimal antiplatelet
therapy after EVT in PAD [6]. DAPT consisting of aspirin
and clopidogrel, which is widely used, is only based on sev-
eral cardiac-related studies [5].
However, even with the same antiplatelet agents, the
effects may differ in cardiovascular disease (CAD) and
PAD. For example, aspirin plus dipyridamol was effective
in patients with CAD but not in those with PAD [7]. In
addition, the incidence of not responding to clopidogrel
was 30% higher in cases of EVT for PAD compared to
percutaneous coronary intervention (PCI) [8]. Although
the reasons for this phenomenon have not been uncov-
ered, it may not be right to use the same DAPT in patients
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with PAD and CVD. Also, the role of antiplatelet therapy
may be reduced or altered by technological developments
in EVT. Therefore, an appropriate evidence-based recom-
mendation of antiplatelet agents after EVT for PAD is
needed.
Sarpogrelate is a selective 5-hydroxytryptamine receptor
2A antagonist that inhibits platelet aggregation, vasocon-
traction, and vascular smooth muscle proliferation [9].
Sarpogrelate is also expected to reduce restenosis by pro-
tecting blood vessels from oxidative stress and vascular
endothelial dysfunction as well as by acting as an anti-
platelet agent after EVT [10].
However, a commercially available immediate-release
formulation of sarpogrelate (100 mg, three times per day)
is not as convenient for patients to use as the currently
used clopidogrel (75 mg, once daily). Fortunately, a
sustained-release (SR) formulation of 300 mg sarpogrelate
hydrochloride for once-daily usage has been introduced to
improve convenience and compliance [11, 12].
This trial was designed to compare aspirin plus SR
sarpogrelate with aspirin plus clopidogrel for the pre-
vention of restenosis (>50% stenosis) at six-month
follow-up in patients with femoro-popliteal (FP) PAD
who underwent EVT.
Methods/Design
Study objectives, hypothesis, and design
This is an open label, multicenter, prospective randomized
controlled clinical trial that will evaluate the efficacy and
safety of aspirin plus SR sarpogrelate in PAD patients
undergoing EVT for FP lesions compared with aspirin
plus clopidogrel (ClinicalTrials.gov, NCT02959606). After
baseline measurements and EVT, participants will be ran-
domly allocated into the aspirin plus clopidogrel group or
the aspirin plus SR sarpogrelate group. A brief flowchart
of the whole study is presented in Figs. 1 and 2.
Study population and eligibility
Patients will be eligible for inclusion in this study if they
require EVT for stenosis or occlusion of a de novo FP
lesion. To be eligible for randomization, patients must
have adequate inflow and outflow (with or without
intervention of the iliac or below-the-knee arteries) and
successful FP intervention (residual stenosis < 30%).
Previous intervention for an FP lesion is an exclusion
criterion. Other inclusion and exclusion criteria are
listed in Table 1.
Intervention and assessment schedule
All patients will be given a loading dose of 300 mg clopi-
dogrel and 100 mg aspirin 24 hours or less before EVT.
However, patients who have been treated with clopido-
grel for > 5 days will receive 75 mg clopidogrel and
100 mg aspirin. Within 24 hours after successful FP
intervention, the patients will be randomly assigned to
the aspirin plus clopidogrel or aspirin plus SR sarpogre-
late groups. Patients in each group will receive aspirin
100 mg with clopidogrel 75 mg or aspirin 100 mg with
SR sarpogrelate 300 mg (Anplone®) orally once a day for
six months.
Follow-up
Outcomes will be recorded at 14 days and three and six
months after intervention (Table 2). Information to be
collected will include clinical and hemodynamic status,
laboratory tests (complete blood cell count, liver func-
tion test, prothrombin time International Normalized
Ratio), ankle–brachial index (ABI), adverse events, and
other health problems and computed tomography angi-
ography (CTA).
Outcome measures
The primary outcome of the study is the restenosis rate,
defined as > 50% luminal reduction by CTA or catheter
angiography in the six-month follow-up period. Second-
ary outcomes include target lesion revascularization,
major bleeding, ipsilateral major amputation, all-cause
mortality, and all adverse events that take place in those
six months.
Fig 1 Flow diagram of SAFE study. EVT endovascular treatment, ASA aspirin, R randomization
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Adverse effects
Recording of serious adverse events (SAE) will con-
form to the Good Clinical Practice standards and the
Research Governance Framework 2005. Analysis of
safety-related data will be performed with respect to
frequency of SAE including all-cause death, stroke, myo-
cardial infarction (MI), or revascularization, early throm-
bosis, major bleeding, and major amputation. MI is
defined as symptoms of ischemia with electrocardio-
graphic changes compatible with MI or cardiac markers at
least twice the upper normal limit [13]. Stroke is defined
as brain hemorrhage, transient ischemic attack, or cerebral
infarction with focal or global neurological deficits with
signs or symptoms confirmed by a neurologist on the
basis of neuroimaging results [14]. Major bleeding is de-
fined as a need for a blood transfusion (≥ 2 packs), surgical
intervention, or hypotension requiring inotropic support
(hemoglobin reduction ≥ 2 g/dL). GUSTO bleeding cri-
teria will be used [15]. Major amputation as a SAE is de-
fine as unplanned above-the-ankle amputation. Early
thrombosis is defined as any event that occurs within
30 days after EVT. SAEs must be reported by the attend-
ing physician to the principal investigator within 24 h after
the SAE becomes known.
Statistical considerations
The aim of this study is to show the non-inferiority of sar-
pogrelate to clopidogrel in preventing restenosis. From
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure (Additional file 1)
Table 1 Study eligibility criteria
Inclusion criteria
Age > 18 years
Angiographically confirmed significant FP stenosis or occlusion
by atherosclerosis
Successful FP intervention (residual stenosis < 30% after EVT)
Without significant residual inflow disease; intact iliac artery
inflow (with or without intervention of iliac or below knee arteries)
Patent outflow status; at least one arterial runoff in BTK
All kind of FP interventions including POBA, stent, DCB, DES for TASC
A ~ D
Exclusion criteria
At risk of hemorrhage, bleeding tendency, or thrombophilia
Acute limb ischemia / inflammatory arterial disease
Contraindication or allergic to ASA, clopidogrel, Anplone
Medication of warfarin
Pregnancy, hepatic dysfunction, thrombocytopenia
Previous FP bypass surgery or intervention
Impossible to stop clopidogrel before EVT
Unable to give informed consent.
FP femoro-popliteal, EVT endovascular treatment, BTK below-the-knee, POBA
plain old balloon angioplasty, DCB drug-coated balloon, DES drug-eluting
stent, TASC The Trans-Atlantic Inter-Society Consensus, ASA aspirin
Ahn et al. Trials  (2017) 18:439 Page 3 of 6
the previous literature, we found a six-month restenosis
rate in patients on clopidogrel of 11% and a six-month re-
stenosis rate in patients on sarpogrelate of 6% following
EVT for FP artery intervention (7). The targeted signifi-
cance level is 2.5%; the sarpogrelate group proportion is
assumed to be 16% under the null hypothesis of inferior-
ity. A sample size of 136 in each group will achieve 80%
power to detect a non-inferiority margin difference be-
tween the group proportions of 5% assuming a dropout
rate of 10%.
Randomization will be done by an independent statis-
tical core at the Medical Research Collaborating Center
of Seoul National University Hospital. Permuted block
randomization will be used with blocks of sizes 4 or 6 to
ensure a balance between the two treatment groups. We
will use SAS 9.4 (SAS institute Inc., Cary, NC, USA) for
sequence generation, which is to be stratified for: (1)
presence of occlusion within the index lesion; (2) use of
stent; (3) TASC classification “A or B” vs. “C or D;” and
(4) presence of critical limb ischemia. Allocation of
treatment will be done via a web-based randomization
system, which returns the treatment group after the in-
put of a participant’s study ID and the inclusion/exclu-
sion criteria.
Characteristics of participants will be summarized using
mean and standard deviation for continuous variables and
frequency and percentage for categorical variables. A two-
sided 95% confidence interval for a difference in restenosis
rate between the two treatment groups will be calculated;
then, whether the upper limit of the confidence interval
should fall within the pre-determined margin of non-
inferiority will be evaluated to prove the non-inferiority of
sarpogrelate to clopidogrel. The conclusion will be based
on the result of intention-to-treat analysis, while the per-
protocol analysis result will be provided by utilizing data
on patients with treatment compliance > 80%. Among the
secondary outcomes, adverse events will be analyzed using
chi-squared tests or Fisher’s exact tests as appropriate.
Major bleeding, ipsilateral amputation, revascularization,
and all-cause mortality will be compared using log-rank
tests and survival curves constructed using Kaplan–Meier
methods.
Significance tests will be two-sided. A P value of
< 0.05 according to SAS will be taken to indicate a statis-
tically significant difference between the groups. SAS 9.4
(SAS institute Inc., Cary, NC, USA) will be used for data
analysis.
Ethical approval
This study follows the principles of the Helsinki Declaration
and all patients will provide written informed consent prior
to participation. Participation can be withdrawn at any time
without any negative consequences concerning current or
future medical treatment. Study approval was given by the
Institutional Review Board of Seoul National University
Hospital (IRB No. 1607-151-778).
Discussion
This study is designed to present evidence of the suit-
ability of antiplatelet agents after endovascular revascu-
larization in patients with FP arterial disease.
Some patients who participate in this study may have
multi-level disease, including inflow or outflow problems
as well as FP lesions, which may need to be corrected
simultaneously. In other words, the inclusion criteria are
broad, which reflects the situation in clinical practice.
We will stratify the data on occlusion of the index lesion,
use of stents, TASC AB and CD, and critical limb ische-
mia, which will help to determine the use of antiplatelet
agent.
To date, DAPT, which consists of aspirin and clopido-
grel, is well documented in patients with PCI. ESC guide-
lines recommend DAPT for one month after EVT with a
stent for PAD [16]. However, the optimal antiplatelet
agent is still unclear in long-term cases. The role of anti-
platelet agents may decline after EVT for PAD owing to
the development of new technology and devices that has
occurred over the past decade [17]. Alternatively, the use
of stronger antiplatelet agents may be required owing to
various forces in the femoral artery during exercise and
more aggressive treatment.
In the CAPRIE study, aspirin alone was associated
with a higher rate of ischemic events than was clopido-
grel [18]. That emphasized the necessity of DAPT rather
than aspirin alone. Especially for cases of MI, ischemic
stroke, and symptomatic PAD, DAPT with clopidogrel
was more effective than ASA alone [19]. On the other
hand, CASPAR failed to demonstrate a benefit of DAPT
(aspirin plus clopidogrel), reminding us of the need for a
Table 2 Assessment schedule
Visit date Visit 1 Visit 2 Visit 3 Visit 4
0 day 14 days 3 months 6 months
Demographic data ○
Medical/surgical history ○






○ ○ ○ ○
Laboratory results
(CBC, LFT, PT INR)
○ ○ ○ ○
ABI ○ ○ ○ ○
CTA or angiography ○ ○
Adverse events ○ ○ ○
CBC complete blood cell count, LFT liver function test, PT prothrombin time
International Normalized Ratio, ABI ankle–brachial index, CTA computed
tomography angiography
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variety of independent studies on the use of antiplatelet
agents in PAD [20].
In one study, sarpogrelate reduced the restenosis rate
(4.6% vs. 28.6%) after six months of coronary stenting
[21]. There are three inhibitory effects of sarpogrelate:
anti-platelet aggregation and anti-vasoconstriction pre-
vent the development of early thrombus and anti-
vascular smooth muscle proliferation is expected to re-
duce in-stent restenosis [9]. In addition, to protect endo-
thelial cells by dose-dependently reducing the ICAM-1
level in a hyperglycemic state, it may also improve long-
term patency after EVT [22].
Considering that patients with PAD are at high risk for
bleeding, sarpogrelate has the potential benefit of lower
bleeding risk compared to clopidogrel [23, 24]. In Korea,
the price of sarpogrelate is lower than that of clopido-
grel, which can reduce medical expenses (US$0.92 vs.
US$1.02 per one tablet). Such potential benefits of sar-
pogrelate may be a good alternative if it is not inferior to
clopidogrel-based DAPT. In conclusion, the SAFE study
is a multicenter randomized controlled trial designed to
show non-inferiority in terms of the re-stenosis rate of
SR sarpogrelate compared to clopidogrel for EVT for
PAD in FP lesion patients. We hope to address these is-
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